Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer

Abstract

The present study evaluates the safety and efficacy of double-plasma filtration (PF) to remove the exceeding pegylated lipposomal doxorubicin (PLD) in ciculation, thus reducing mucocutaneous toxicity. PF can be considered as safe and effective for the extracorporeal removal of PLD, resulting in a lower incidence of mucocutaneous toxicity.

Keywords

• cancer therapy
• ovarian cancer
• EPR effect
• population kinetics
• pegylated liposomal doxorubicin (PLD)
• mucocutaneous toxicity
• hand-foot syndrome
• plasmapheresis